{"id":28848,"date":"2026-02-24T11:06:32","date_gmt":"2026-02-24T11:06:32","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=28848"},"modified":"2026-02-24T12:18:37","modified_gmt":"2026-02-24T12:18:37","slug":"astella-and-vir-biotechnology-sign-global-deal-for-vir-5500","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/","title":{"rendered":"Astella\u793e\u3068Vir Biotechnology\u793e\u304cVIR-5500\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u5951\u7d04\u3092\u7de0\u7d50"},"content":{"rendered":"<p>\u30a2\u30b9\u30c6\u30e9\u30b9\u88fd\u85ac\u682a\u5f0f\u4f1a\u793e\u3068 Vir Biotechnology, Inc.\u306f\u3001PSMA \u6a19\u7684\u306e PRO-XTEN \u30c7\u30e5\u30a2\u30eb\u30de\u30b9\u30af CD3 T \u7d30\u80de\u30a8\u30f3 \u30b2\u30a4\u30b8\u30e3\u30fc\u3067\u3042\u308b VIR-5500 \u306e\u524d\u7acb\u817a\u764c\u306e\u958b\u767a\u30fb\u5546\u696d\u5316\u306b\u5411\u3051\u3066\u4e16\u754c\u7684\u306b\u63d0\u643a\u3057\u307e\u3059\u3002\u5c0f\u3055\u306a\u52d5\u304d\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u3053\u306e\u7814\u7a76\u306f\u3001\u751f\u5b58\u7387\u306b\u8ab2\u984c\u304c\u3042\u308a\u3001\u60a3\u8005\u304c\u73fe\u5728\u306e\u6cbb\u7642\u6cd5\u306b\u8010\u6027\u3092\u7372\u5f97\u3057\u305f\u5f8c\u306e\u6cbb\u7642\u6cd5\u306e\u9078\u629e\u80a2\u304c\u9650\u3089\u308c\u3066\u3044\u308b\u8ee2\u79fb\u6027\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\u306b\u7126\u70b9\u3092\u5f53\u3066\u3066\u3044\u307e\u3059\u3002.<\/p>\n<p>VIR-5500\u306e\u73fe\u72b6\u306f\u3001\u9032\u884c\u6027\u8ee2\u79fb\u6027\u524d\u7acb\u817a\u764c\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2c1\u76f8\u8a66\u9a13\u3067\u3059\u3002\u3053\u3053\u3067\u91cd\u8981\u306a\u306e\u306f\u79d1\u5b66\u7684\u306a\u5074\u9762\u3067\u3059\u3002VIR-5500\u306fPSMA\u3068CD3\u306b\u7d50\u5408\u3057\u307e\u3059\u304c\u3001PRO-XTEN\u306e\u30de\u30b9\u30ad\u30f3\u30b0\u6280\u8853\u3092\u4f7f\u7528\u3057\u3066\u3044\u308b\u306e\u3067\u3001T\u7d30\u80de\u30a8\u30f3\u30b2\u30a4\u30b8\u30e3\u30fc\u306f\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u5230\u9054\u3059\u308b\u307e\u3067\u4e0d\u6d3b\u6027\u3067\u3059\u3002\u8003\u3048\u65b9\u306f\u7c21\u5358\u3002\u816b\u760d\u3092\u653b\u6483\u3002\u30aa\u30d5\u30bf\u30fc\u30b2\u30c3\u30c8\u30fb\u30c0\u30e1\u30fc\u30b8\u3092\u6291\u5236\u3002\u6cbb\u7642\u52b9\u679c\u3092\u9ad8\u3081\u308b.<\/p>\n<p>\u3055\u3066\u3001\u53d6\u5f15\u306e\u69cb\u9020\u3002Vir\u306f\u5951\u7d04\u4e00\u6642\u91d1\u3068\u77ed\u671f\u7684\u306a\u652f\u6255\u3044\u30673\u51043500\u4e07\u30c9\u30eb\u3092\u7372\u5f97\u3002\u305d\u306e\u5185\u8a33\u306f\u3001\u73fe\u91d12\u51044,000\u4e07\u30c9\u30eb\u300150\uff05\u306e\u30d7\u30ec\u30df\u30a2\u30e0\u3067\u682a\u5f0f\u5316\u3055\u308c\u308b7,500\u4e07\u30c9\u30eb\u3001\u77ed\u671f\u7684\u306a\u76ee\u6a19\u9054\u6210\u306e\u305f\u3081\u306b\u652f\u6255\u308f\u308c\u308b2,000\u4e07\u30c9\u30eb\u3002Vir\u793e\u306f\u3001\u3059\u3079\u3066\u306e\u958b\u767a\u304a\u3088\u3073\u898f\u5236\u30fb\u8ca9\u58f2\u9054\u6210\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u3092\u901a\u3058\u306613\u51047,000\u4e07\u30c9\u30eb\u3092\u53d7\u3051\u53d6\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u7c73\u56fd\u5916\u3067\u306e\u58f2\u4e0a\u9ad8\u306b\u3064\u3044\u3066\u306f\u3001\u6bb5\u968e\u7684\u306a2\u6841\u306e\u30ed\u30a4\u30e4\u30eb\u30c6\u30a3\u3092\u53d7\u3051\u53d6\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002.<\/p>\n<h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/japan-authorizes-first-ips-cell-derived-therapies-marking-breakthrough-in-regenerative-medicine\/\" rel=\"bookmark\">\u65e5\u672c\u521d\u306eiPS\u7d30\u80de\u7531\u6765\u6cbb\u7642\u85ac\u3092\u627f\u8a8d\u3001\u518d\u751f\u533b\u7642\u306e\u30d6\u30ec\u30fc\u30af\u30b9\u30eb\u30fc\u306b<\/a><\/h4>\n<p>\u958b\u767a\u8cbb\u306f\u6298\u534a\u3002\u30a2\u30b9\u30c6\u30e9\u30b9\u88fd\u85ac\u304c60\uff05\u3002Vir\u793e\u304c40\uff05\u3002\u9032\u884c\u4e2d\u306e\u30d5\u30a7\u30fc\u30ba1\u8a66\u9a13\u306f\u5f53\u9762Vir\u793e\u304c\u7d99\u7d9a\u3002\u79fb\u884c\u5f8c\u306f\u30a2\u30b9\u30c6\u30e9\u30b9\u88fd\u85ac\u304c\u958b\u767a\u696d\u52d9\u3092\u5f15\u304d\u7d99\u304e\u307e\u3059\u3002\u7c73\u56fd\u5185\u3067\u306f\u640d\u76ca\u3092\u6298\u534a\u3057\u3001Vir\u793e\u306f\u5171\u540c\u8ca9\u4fc3\u306e\u30aa\u30d7\u30b7\u30e7\u30f3\u3092\u4fdd\u6709\u3002\u7c73\u56fd\u5916\u3067\u306f, <a href=\"https:\/\/www.astellas.com\/\">\u30a2\u30b9\u30c6\u30e9\u30b9\u88fd\u85ac<\/a> \u306f\u72ec\u5360\u7684\u5546\u696d\u5316\u6a29\u3092\u53d6\u5f97\u3002.<\/p>\n<p>\u3082\u3046\u3072\u3068\u3064\u3042\u308a\u307e\u3059\u3002Vir\u793e\u3068\u30b5\u30ce\u30d5\u30a3\u793e\u3068\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u5951\u7d04\u3067\u306f\u3001\u5171\u540c\u7814\u7a76\u306b\u3088\u308b\u53ce\u76ca\u306e\u4e00\u90e8\u306f\u30b5\u30ce\u30d5\u30a3\u793e\u3068\u5171\u6709\u3055\u308c\u308b\u3053\u3068\u306b\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u30e9\u30b6\u30fc\u30c9\u306f <a href=\"https:\/\/www.vir.bio\/\">\u30a6\u30a4\u30eb\u30b9<\/a> \u53d6\u5f15\u306b\u3064\u3044\u3066\u30af\u30ed\u30fc\u30b8\u30f3\u30b0\u306f\u3001\u30cf\u30fc\u30c8\uff1d\u30b9\u30b3\u30c3\u30c8\uff1d\u30ed\u30c7\u30a3\u30fc\u30ce\u6cd5\u306b\u57fa\u3065\u304f\u30af\u30ea\u30a2\u30e9\u30f3\u30b9\u3092\u542b\u3080\u3001\u6a19\u6e96\u7684\u306a\u6761\u4ef6\u6b21\u7b2c\u3067\u3059\u3002.<\/p>\n<p>VIR\u793e\u306f\u307e\u305f\u30012025\u5e74\u7b2c4\u56db\u534a\u671f\u304a\u3088\u3073\u901a\u671f\u306e\u6c7a\u7b97\u3068\u4e26\u884c\u3057\u3066\u96fb\u8a71\u4f1a\u8b70\u3092\u958b\u50ac\u3057\u30012026\u5e74ASCO Genitourinary Cancers Symposium\u3067\u767a\u8868\u3055\u308c\u308b\u30c7\u30fc\u30bf\u3092\u542b\u3081\u3001VIR-5500\u306e\u7b2c1\u76f8\u30c7\u30fc\u30bf\u306e\u66f4\u65b0\u306b\u3064\u3044\u3066\u8aac\u660e\u3057\u307e\u3059\u3002.<\/p>\n<p>\u816b\u760d\u5b66\u306e\u5927\u304d\u306a\u8ced\u3051\u3002\u30ea\u30b9\u30af\u306e\u5171\u6709\u3002\u30a2\u30c3\u30d7\u30b5\u30a4\u30c9\u306e\u5171\u6709\u3002\u3042\u3068\u306f\u81e8\u5e8a\u30c7\u30fc\u30bf\u304c\u4f55\u3092\u793a\u3059\u304b\u3002.<\/p>","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. and Vir Biotechnology, Inc. are teaming up globally to develop and commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked CD3 T-cell engager for prostate cancer. Not a small move. This research focuses on metastatic castration-resistant prostate cancer which presents challenges in survival rates and provides limited treatment choices after patients develop resistance to current therapies. The current status of VIR-5500 involves its Phase 1 trial for patients with advanced metastatic prostate cancer. The science angle matters here. It binds to PSMA and CD3, but uses PRO-XTEN masking technology so the T-cell engager stays inactive until it reaches the tumor microenvironment. The idea is simple. Hit the tumor. Limit off-target [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":28876,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[11612,424,11614,11613,11611],"ppma_author":[572],"class_list":{"0":"post-28848","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-tech","8":"category-international","9":"category-news","10":"category-pharma","11":"tag-astellas","12":"tag-pharma","13":"tag-pro-xten","14":"tag-t-cell-engager","15":"tag-vir-biotechnology"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Astellas teams with Vir Biotechnology on VIR-5500 globally<\/title>\n<meta name=\"description\" content=\"Astellas and Vir to develop VIR-5500, a PSMA-targeting T-cell therapy for metastatic prostate cancer with limited treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas teams with Vir Biotechnology on VIR-5500 globally\" \/>\n<meta property=\"og:description\" content=\"Astellas and Vir to develop VIR-5500, a PSMA-targeting T-cell therapy for metastatic prostate cancer with limited treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T11:06:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T12:18:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/1-2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Astellas teams with Vir Biotechnology on VIR-5500 globally","description":"Astellas and Vir to develop VIR-5500, a PSMA-targeting T-cell therapy for metastatic prostate cancer with limited treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/","og_locale":"ja_JP","og_type":"article","og_title":"Astellas teams with Vir Biotechnology on VIR-5500 globally","og_description":"Astellas and Vir to develop VIR-5500, a PSMA-targeting T-cell therapy for metastatic prostate cancer with limited treatment options.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/","og_site_name":"itbusinesstoday","article_published_time":"2026-02-24T11:06:32+00:00","article_modified_time":"2026-02-24T12:18:37+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/1-2.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Astella and Vir Biotechnology sign global deal for VIR-5500","datePublished":"2026-02-24T11:06:32+00:00","dateModified":"2026-02-24T12:18:37+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/"},"wordCount":352,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/1-2.webp","keywords":["Astellas","Pharma","PRO-XTEN","T cell engager","Vir Biotechnology"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/","name":"Astellas teams with Vir Biotechnology on VIR-5500 globally","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/1-2.webp","datePublished":"2026-02-24T11:06:32+00:00","dateModified":"2026-02-24T12:18:37+00:00","description":"Astellas and Vir to develop VIR-5500, a PSMA-targeting T-cell therapy for metastatic prostate cancer with limited treatment options.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/1-2.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/02\/1-2.webp","width":1200,"height":800,"caption":"Astellas"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/astella-and-vir-biotechnology-sign-global-deal-for-vir-5500\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Astella and Vir Biotechnology sign global deal for VIR-5500"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/28848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=28848"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/28848\/revisions"}],"predecessor-version":[{"id":28850,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/28848\/revisions\/28850"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/28876"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=28848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=28848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=28848"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=28848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}